Review of the Diagnosis and Treatment of Periodic Paralysis by J.M. Statland et al.
INVITED REVIEW
REVIEW OF THE DIAGNOSIS AND TREATMENT
OF PERIODIC PARALYSIS
JEFFREY M. STATLAND, MD ,1 BERTRAND FONTAINE, MD, PhD,2 MICHAEL G. HANNA, MD,3
NICHOLAS E. JOHNSON, MD,4 JOHN T. KISSEL, MD,5 VALERIA A. SANSONE, MD,6 PERRY B. SHIEH, MD, PhD,7
RABI N. TAWIL, MD, MS,8 JAYA TRIVEDI, MD,9 STEPHEN C. CANNON, MD,10 and ROBERT C. GRIGGS, MD8
1Department of Neurology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, USA
2Sorbonne-Universite, INSERM, AP-HP, Reference Center for Channelopathies, Department of Neuology, University Hospital
Pitie-Salpe^trie`re, Paris, France
3MRC Center for Neuromuscular Diseases, University College of London Institute of Neurology, London, England
4Department of Neurology, University of Utah School of Medicine, Salt Lake City, Utah, USA
5Department of Neurology, The Ohio State University, Columbus, Ohio, USA
6The NEMO Center, Neurorehabilitation Unit, University of Milan, Italy
7Department of Neurology, University of California at Los Angeles School of Medicine, Los Angeles, California, USA
8Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
9Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
10Department of Physiology, University of California at Los Angeles School of Medicine, Los Angeles, California, USA
Accepted 7 November 2017
ABSTRACT: Periodic paralyses (PPs) are rare neuromuscular
disorders caused by mutations in skeletal muscle sodium, calcium,
and potassium channel genes. PPs include hypokalemic paralysis,
hyperkalemic paralysis, and Andersen-Tawil syndrome. Common
features of PP include autosomal dominant inheritance, onset typi-
cally in the first or second decades, episodic attacks of flaccid
weakness, which are often triggered by diet or rest after exercise.
Diagnosis is based on the characteristic clinic presentation then
confirmed by genetic testing. In the absence of an identified
genetic mutation, documented low or high potassium levels during
attacks or a decrement on long exercise testing support diagnosis.
The treatment approach should include both management of acute
attacks and prevention of attacks. Treatments include behavioral
interventions directed at avoidance of triggers, modification of
potassium levels, diuretics, and carbonic anhydrase inhibitors.
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Primary periodic paralyses (PPs) are rare autosomal-
dominant genetic neuromuscular disorders associ-
ated with mutations in the skeletal muscle sodium,
calcium, and potassium channels.1,2 Common to all
PP are attacks of muscle paralysis, which may last
minutes to hours or days and cause morbidity and
impaired quality of life.3,4 The attacks are often trig-
gered by behavior or diet, and often are associated
with alterations in serum potassium levels. In all forms
of PP, ictal paresis is caused by depolarization of the
muscle sarcolemma, which in turn causes sodium
channel inactivation and reduced fiber excitability.1,2
Primary periodic paralyses include hypokalemic
paralysis (HypoPP), hyperkalemic paralysis
(HyperPP), and Andersen-Tawil syndrome. There
are also closely related diseases whose features over-
lap with HypoPP and HyperPP, including paramyo-
tonia congenita (PMC) and normokalemic PP. In
most instances, these diseases are caused by muta-
tions of the sodium channel. The sodium channel
mutations present as a spectrum of disorders, rang-
ing from pure myotonic disorders to disorders
which primarily have myotonia with episodic weak-
ness (e.g., PMC) to disorders with primary episodic
weakness with occasional myotonia (HyperPP and
normokalemic PP). There is some overlap, and the
determination of whether to classify a disorder as
PMC or HyperPP will depend on the predominant
symptoms. Estimated prevalences for the periodic
paralyses are 1 per 200,000 for HyperPP,5,6 1 per
100,000 for HypoPP,5,7 and 1 per 1,000,000 for
Andersen-Tawil syndrome,8 although a study in the
United Kingdom identified a lower prevalence for
many of the channelopathies.9 Nevertheless, these
diseases are rare in the general population and as a
consequence prospective clinical studies of treat-
ment interventions are limited.
Additional supporting information may be found in the online version of
this article.
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Treatment options include avoidance of trig-
gers, potassium supplementation to increase potas-
sium levels, and carbonic anhydrase inhibitors.
Because of the low prevalence of primary PP and
limited treatment options, few prospective studies
are available to guide management recommenda-
tions, which are primarily based on anecdotal evi-
dence and patient case reports.
This review addresses the diagnosis and treat-
ment of primary PP. The recommendations are
based on published literature and on experience of
clinicians in managing patients with PP.
TYPES OF PRIMARY PERIODIC PARALYSIS
Most individuals with primary PP have inherited
autosomal dominant disorders; sporadic cases also
occur, although the frequency is unknown.10 While
all of the familial disorders can be attributed to
genetic mutations in muscle ion channels, they differ
in their genetics, signs and symptoms, and treatment.
HypoPP is associated with mutations in calcium
channel (CACNA1S; 60% of kindreds) and sodium
channel (SCN4A; 20% of kindreds) genes.11–15 The
clinical presentation is identical for patients with
HypoPP caused by calcium or sodium channel
mutations because homologous gene defects of
either channel cause an anomalous leakage cur-
rent, which is active at the resting potential and
produces susceptibility to paradoxical depolariza-
tion of the fiber and inexcitability in the setting of
low extracellular K1 (2.5 to 3.5 Meq/L).1,12
HyperPP is associated with mutations in the
sodium channel (SCN4A) gene on chromosome
17q23.11–15 These mutations are associated with gain
of function changes, usually from impaired channel
inactivation or occasionally from enhanced activation.
Andersen-Tawil syndrome in some cases is caused
by mutations of the KCNJ2 gene, which encodes the
inward rectifier potassium channel, Kir2.1, stabilizing
resting potential of skeletal muscle and cardiac myo-
cytes.8 UnlikeHypoPP andHyperPP, which are limited
to mutations in channels expressed almost exclusively
in skeletal muscle, the potassium channel mutations
leading to Andersen-Tawil syndrome affect multiple
tissues, and are associated with a highly variable
phenotype of periodic paralysis, cardiac arrhythmia,
and distinctive facial and skeletal anomalies.2,16
GENERAL CLINICAL PRESENTATION
Patients with PP experience an onset of signs
and symptoms typically beginning in the first or sec-
ond decade of life (Table 1). Patients generally
present with intermittent attacks of focal or general-
ized muscle weakness, often precipitated by trig-
gers.10,17,18 Patients can develop between-attack
weakness of varying severity, and the majority of
affected individuals manifest persistent weakness
later in life.19–21
In addition to its effects on strength, PP is associ-
ated with impairments of quality of life due to mus-
cle weakness, myotonia, fatigue, loss of energy, and
a reduced ability to participate in social and family
life, including school and sporting activities.3,4
The effect of PP on quality of life was assessed
from patient surveys and a clinical study.3,4,22 An on-
line survey of 66 patients with HypoPP (46), HyperPP
(6), PMC (4), Andersen-Tawil syndrome (6), or un-
known cause (4) found permanent weakness in 68%,
muscle pain in 82%, and muscle fatigue in 89%.3
Beginning at age 18–35 years, 83% self-reported that
they were moderately to very active compared with
14% at the time of the survey (mean age, 60 years),
67% incurred injuries due to falls, and 49% required
mobility aids. Sansone et al4 assessed quality of life in
66 patients with skeletal muscle channelopathies
including 26 patients with periodic paralyses and 4
with Andersen-Tawil syndrome. Quality of life was
impaired in all patients, but especially impacted were
muscle weakness in HypoPP patients, myotonia in
HyperPP patients, fatigue in Andersen-Tawil syn-
drome, and energy in all patients.
Clinical Presentation of HypoPP. HypoPP is charac-
terized by focal or generalized paralytic episodes of
skeletal muscle, which can last hours to days and are
associated with concomitant hypokalemia (<2.5
mEq/L). A variable myopathy develops in many
affected individuals and may result in a progressive
muscle weakness predominantly in proximal muscle
groups of the lower limbs. The myopathy may occur
Table 1. Clinical presentation of PPPs
Feature HypoPP HyperPP
Andersen-Tawil
syndrome
Ictal K1 level Low High/normal Variable
Age at onset Age 5–35 y Before age 20 y Age 2–18 y
Mean duration of episodes >2h <2h 1 to 36 h
Muscle stiffness Absent Moderate Absent
Episodic weakness Yes Yes Yes
Maximum weakness Severe Mild to severe Moderate
Characteristic facies Absent Absent Present
Arrhythmias Absent Absent Long QT arrhythmia
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independent of paralytic symptoms.6 Patients with
HypoPP are at increased risk for pre- or postanes-
thetic weakness. Late-onset proximal myopathy may
develop in some patients.2
The first attack usually occurs between ages 5
and 35 years, but the frequency of attacks is high-
est between ages 15 and 35 years and subsequently
decreases with age.1,10 Acute attacks occur repeat-
edly at daily, weekly or monthly intervals and typi-
cally last several hours and sometimes days. Attacks
can occur both spontaneously, but also in response
to triggers such as carbohydrate-rich meals, alco-
hol, and rest after strenuous exercise.1,10
Clinical Presentation of HyperPP. Characteristic fea-
tures of HyperPP are attacks of limb weakness and
an increase of serum potassium during an attack,
but some patients have normal serum potassium lev-
els during attacks.23 Administration of potassium
may trigger an attack or worsen an ongoing episode.
Attacks of muscle weakness begin in the first
decade of life in approximately 50% of patients,
with only 25% reporting their first attack at age 10
years. Attacks may be triggered by potassium-rich
food, rest after exercise, fasting, exposure to cold,
emotional stress or pregnancy and often begin in
the morning lasting up to 2 h.1,10 Between attacks,
approximately half of patients with HyperPP experi-
ence muscle stiffness arising from myotonia or
paramyotonia that does not impede voluntary move-
ments. More than 80% of patients older than 40
years with HyperPP experience permanent muscle
weakness, and one third develop chronic progres-
sive myopathy. Attacks in HyperPP tend to be more
frequent and shorter in duration than attacks in
HypoPP.18 Patients with PMC complain of muscle
stiffness, often exacerbated by cold temperatures
that may progress to weakness.18
Clinical Presentation of Andersen-Tawil Syndrome. An-
. Andersen-Tawil syndrome is characterized by a
triad of episodic flaccid muscle weakness (periodic
paralysis), cardiac abnormalities (ventricular arr-
hythmias, prolonged QT interval, and prominent
U waves), and distinctive skeletal features (low-set
ears, ocular hypertelorism, small mandible, fifth-
digit clinodactyly, syndactyly, short stature, scolio-
sis, and a broad forehead).16,24 This characteristic
triad is present in 58–78% of patients with KCNJ2
mutations.25,26 Those affected typically present
in the first or second decade with either cardiac
symptoms (palpitations and/or syncope) or weak-
ness that occurs spontaneously following pro-
longed rest or following rest after exertion.
Permanent weakness is common. Attacks of muscle
weakness can be associated with high, low or nor-
mal serum potassium levels.16
Andersen-Tawil syndrome is a potentially fatal
condition.27–29 In patients with the KCNJ2 gene
mutation, ventricular arrhythmias are common
(Table 1).27–29 Cardiac manifestations of Andersen-
Tawil syndrome include premature ventricular
contractions (PVCs), complex ventricular ectopy
(bigeminy, consecutive PVCs, or multifocal PVCs),
polymorphic ventricular tachycardia (VT), and bidi-
rectional VT.29 Despite the common occurrence of
ventricular arrhythmias, syncope or cardiac arrest is
rare.27,30 Early identification and diagnosis of these
patients is important for treatment optimization.
DIAGNOSIS
The diagnosis of PP can be confirmed by
genetic testing, which we recommend as the first
diagnostic step when there is an intermediate-to-
high clinical suspicion.31 All PPs are inherited in
an autosomal dominant manner. Genetic testing
identifies a heterozygous pathogenic mutation in
60% to 70% of patients meeting clinical crite-
ria.15,17 For HypoPP, the gene is CACNA1S (CaV.1)
or SCN4A and the chromosome is 1q31-32 or
17q23-25; for HyperPP, the gene is SCN4A (NaV
1.4) and the chromosome is 17q23-25; and for
Andersen-Tawil syndrome, the gene is KCNJ2
(Kir2.1) and the chromosome is 17q23. Several
mutations have been associated with thyrotoxic
HypoPP, most commonly KCNJ18, which may be
seen in up to 3% of patients with HypoPP,32 and
KCNE3, which was originally associated with
HypoPP, but whose association is currently contro-
versial.14 More recently mutations in the gene
KCNJ5 have been implicated in one family with
Andersen-Tawil syndrome, and then subsequently
found in 1/21 gene negative Andersen-Tawil syn-
drome, but this will require verification in separate
cohorts.33
In the absence of an identified genetic muta-
tion in approximately 30% of patients, periodic
paralysis subtypes can be distinguished on the basis
of clinical presentation, serum potassium levels
during attacks, and pattern of abnormalities on
long exercise testing.10,15,23,31,34 If primary PP is
suspected but cannot be confirmed by genetic test-
ing, further examination should be undertaken to
confirm that the symptoms are not secondary to
other conditions such as thyrotoxicosis35 or sec-
ondary causes of blood potassium deficiency or
excess (Tables 2 and 3).
Electrodiagnostic testing has been a mainstay
to demonstrate evidence of muscle fiber changes
in excitability in the muscle channelopathies. On
needle electromyography (EMG), positive sharp
waves and myotonia, characterized by spontaneous
waxing and waning motor unit potential amplitude
and frequency, can be seen in PMC and HyperPP.
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In PP, long exercise testing has largely replaced
provocative maneuvers, which induce full body
attacks of paralysis. In the long exercise test a focal
attack of paralysis is induced by exercise of a single
muscle. The patient is instructed to perform
repeated isometric contractions of the abductor
digiti minimi muscle over 5min (in 15-s blocks
alternating with 3–4 s of rest), and compound
muscle action potentials (CMAPs) are recorded
after supramaximal stimulation of the ulnar nerve
every minute or every other minute for 40–60min
postexercise. A reduction in CMAP amplitude of
40% or more from the maximal during exercise or
post exercise is considered abnormal and is typi-
cally seen in >70% of patients.31,36,37
Several symptoms or signs, or test results, can
suggest an alternative diagnosis.7,38 The first attack
most commonly occurs in the first 2 decades of
life, and rarely after 30 years of age. Prominent
sensory symptoms or pain or autonomic symptoms
during the attacks may indicate Guillain-Barre syn-
drome or spinal cord injury. Alteration of con-
sciousness or abnormal movements may be
indicative of seizure or stroke. Symptoms such as
double vision, ptosis, or difficulty swallowing might
point to a neuromuscular junction disorder. Dur-
ing the attacks, the motor exam should reveal a
flaccid paralysis, so preservation of reflexes in a
paralyzed limb should raise the possibility of a dif-
ferent cause. When interpreting genetic testing it
is important to put the results in the clinical con-
text. A known pathological mutation in the typical
clinical context is confirmatory. Variants of
unknown significance may require testing of addi-
tional family members, or further functional test-
ing of the mutation in vitro to fully resolve its
significance.
Andersen-Tawil Syndrome. Andersen-Tawil syn-
drome occurs with a high degree of phenotypic
variability rendering diagnosis very difficult. Muta-
tions in the KCNJ2 gene are identified in approxi-
mately 60% of all individuals with the disorder; a
genetic mutation is not identified in the remaining
40% of cases where the cause is unknown. In those
with KCNJ2 mutations, hyperkalemic episodes
occur in approximately 15% of patients, normoka-
lemic episodes in approximately 20% of patients,
and the remainder have hypokalemic episodes of
paralysis that are similar to those seen in HypoPP.8
The presence of characteristic physical features
and/or electrocardiographic (ECG) abnormalities
is consistent with a diagnosis of Andersen-Tawil
syndrome.18,24 Typical resting ECG abnormalities
include a long QTc or long QU interval in the
absence of hypokalemia. When the diagnosis of
Andersen-Tawil syndrome is suspected, electrophys-
iological studies including the long exercise proto-
col may help support the diagnosis.31,39
The primary diagnostic criterion is documenta-
tion of the KCNJ2 mutation. In the absence of an
Table 3. Supportive diagnostic criteria for HyperPP
1. Two or more attacks of muscle weakness with documented serum K >4.5 mEq/L
2. One attack of muscle weakness in the proband, and 1 attack of weakness in 1 relative with documented serum K
>4.5 mEq/L in at least 1 attack
3. Three of 6 clinical or laboratory features:
a. Onset before third decade
b. Attack duration (muscle weakness involving 1 or more limbs)<2 hours
c. Positive triggers (exercise, stress)
d. Myotonia
e. Positive family history or genetically confirmed skeletal sodium channel mutation
f. Positive McManis long exercise test
4. Exclusion of other causes of hyperkalemia (renal, adrenal, thyroid dysfunction; potassium-sparing diuretics use)
Table 2. Supportive diagnostic criteria for HypoPP
1. Two or more attacks of muscle weakness with documented serum K <3.5 mEq/L
2. One attack of muscle weakness in the proband, and 1 attack of weakness in 1 relative with documented serum K <3.5 mEq/L
in at least 1 attack
3. Three of 6 clinical or laboratory features:
a. Onset in the first or second decade
b. Attack duration (muscle weakness involving 1 or more limbs)>2 hours
c. Positive triggers (high carbohydrate rich meal, rest after exercise, stress)
d. Improvement with potassium intake
e. Positive family history or genetically confirmed skeletal calcium or sodium channel mutation
f. Positive McManis long exercise test
4. Exclusion of other causes of hypokalemia (renal, adrenal, thyroid dysfunction; renal tubular acidosis; diuretic and laxative abuse)
5. Absence of myotonia (clinically or latent detected by needle EMG), except eye lids
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identified genetic mutation, Andersen-Tawil syn-
drome should be suspected in individuals with
either A or B in Table 4.24
GENERAL TREATMENT CONSIDERATIONS
A progressive strategy should be used begin-
ning with patient education and lifestyle changes
to minimize triggers of PP, and then potassium
therapy (supplement or avoidance) followed by
use of carbonic anhydrase inhibitors. As an initial
step, discussion of triggering factors, especially
diet, may be of benefit to decrease the number of
attacks. Professional advice from a dietician may be
beneficial. An understanding of the episodic
nature of the disease is important for children,
and health officials should be informed at schools
where children with periodic paralysis are enrolled.
If the potassium level during attacks is unknown,
behavioral strategies for acute attacks should be
used (e.g., mild exercise at attack onset).
Pharmacological interventions consist of therapy
to abort acute attacks and chronic preventive ther-
apy to reduce attack frequency.18 Treatment options
for periodic paralyses are limited, and aside from
the recent Food and Drug Administration (FDA)
approval of dichlorphenamide, are based largely on
anecdotal experience (Table 5).22,40,41
Carbonic anhydrase inhibitors (in particular
acetazolamide and dichlorphenamide) have been
used for almost 50 years as empiric treatment for
both HypoPP and HyperPP.1,40,42 The mechanism
of action in periodic paralyses is incompletely
understood. Carbonic anhydrase inhibitors pro-
mote kaliuresis and a nonanion gap acidosis by
increasing urinary bicarbonate excretion. The sys-
temic acidosis may reduce the susceptibility to peri-
odic paralysis.1,34,43 An alternative proposal is
enhanced opening of calcium-activated K chan-
nels.44 In addition, carbonic anhydrase inhibitors
also may be effective for treating permanent weak-
ness in HypoPP by reducing intracellular sodium
accumulation.45 This lessens damage to the struc-
ture of muscle fiber, thus allowing the remaining
muscle fibers to regenerate. However, whether
these pharmacological effects are directly responsi-
ble for the benefits of carbonic anhydrase inhi-
bitors in PP remains poorly understood.42 The
interval between attacks varies widely, and the
interval may be prolonged by treatment with potas-
sium or carbonic anhydrase inhibitors.
Those with HypoPP caused by an SCN4A muta-
tion are less responsive to carbonic anhydrase
inhibitors or may even experience worsening of sym-
ptoms. In a study of 74 patients with HypoPP who
were genotyped, the overall response to acetazol-
amide was 46%, but the response differed by geno-
type.40 Among those with the CACNA1S mutation,
the response was 56% (31/55), but among those
with the SCN4A mutation the response was 16% (3/
19). Exacerbation of HypoPP with acetazolamide
has been reported in patients with the SCN4A muta-
tion.46,47 Specific gene defects have been associated
with clinical worsening on carbonic anhydrase in-
hbitors. Acetazolamide caused worsening for several
patients with the SCN4A HypoPP mutations R672G
or R672S and in one patient with the CACNA12S
mutation R1239H.48,49 Another report describes 3
patients with HypoPP who worsened with acetazol-
amide treatment but subsequently responded to
treatment with dichlorophenamide.19
Acetazolamide is routinely used for treating PP.
No randomized, controlled studies have been per-
formed with acetazolamide in PP, but rather its use
is based on the results of nonrandomized, single-
blind trials and anecdotal reports.23 Overall, approx-
imately 50% of patients respond to acetazolamide.40
Common side effects of carbonic anhydrase
inhibitors include paresthesia, fatigue, and mild,
reversible cognitive disturbances.22,50 An additional
concern with carbonic anhydrase inhibitors is an
increased risk of nephrolithiasis. In 1 report, 3 of
20 (15%) patients receiving long-term treatment
with acetazolamide for myotonia experienced nep-
hrolithiasis.51 Nephrolithiasis has been widely
reported with acetazolamide when used for other
Table 4. Supportive diagnostic criteria for Andersen-Tawil syndrome.24
A. Presence of 2 of the following 3 criteria:
- Periodic paralysis
- Symptomatic cardiac arrhythmias or ECG evidence of enlarged U-waves, ventricular ectopy or a prolonged QTc or QUc interval
- Characteristic facies, dental anomalies, small hands and feet, and at least 2 of the following:
- Low-set ears
- Widely spaced eyes
- Small mandible
- Fifth-digit clinodactyly
- Syndactyly of toes 2 and 3
B. One of the above 3 in addition to at least 1 other family member who meets 2 of the 3 criteria.18,24,30
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conditions,52 and may be managed by removal of
renal calculi without necessitating discontinuation
of carbonic anhydrase inhibitor treatment.51
Dichlorphenamide was recently approved by the
FDA for the treatment of PP. Dichlorphenamide has
been evaluated in four randomized, placebo-
controlled studies, two each in patients with HypoPP
and HyperPP (Supplementary Table 1, which is avail-
able online).22,53 The dose of dichlorphenamide was
50mg twice daily for treatment-na€ıve patients. Pa-
tients already on dichlorphenamide before the study
continued on the same dose during the study. In
patients taking acetazolamide before the study, the
dose of dichlorphenamide was set at 20% of the acet-
azolamide dose. Dose reduction for tolerability was
permitted. The mean dose of dichlorphenamide at
Week 9 was 82mg/day. While randomized controlled
trials of dichlorphenamide were performed in adults,
the same approach is taken for children. Dose adjust-
ments may be required based on age.
These studies demonstrated a significant reduc-
tion in the frequency and severity of the attacks.
The most common side effects with dichlorphena-
mide were paresthesias, cognitive disorder, dysgeu-
sia, headache, fatigue, hypoesthesia, and muscle
spasms,22 generally not requiring discontinuation
of dichlorphenamide, and reversible with drug dis-
continuation. During a 52-week extension, in
which all remaining patients received open-label
dichlorphenamide, continued improvement in out-
comes was observed in both placebo and dichlor-
phenamide groups (Supplementary Table 2).22
In one of the studies of diclorphenamide, quality
of life was assessed at 9 weeks with the SF-36.22 No
significant improvement was observed in patients
with HyperPP, but significant improvement was
reported for the physical component and physical
functioning, role physical, bodily pain, vitality, and
social functioning in those with HypoPP.
Other pharmacological treatments for periodic
paralyses depend on serum potassium levels and the
specific diagnosis but include potassium supplemen-
tation, thiazide or potassium-sparing diuretics or
beta-adrenergic agents.42,54 For patients receiving
chronic potassium supplementation for HypoPP,
providers can consider adding magnesium, which
can be helpful to promote renal retention of K1
and, therefore, reduce the potassium dose.
Management of HypoPP. Acute management. Mild
exercise (e.g., nonresistance activities such as walk-
ing around a room or shaking the arms) at the onset
Table 5. General approach to treatment for primary periodic paralyses.1,4,6,24
HyperPP HypoPP Andersen-Tawil syndrome
Acute attack
Non-pharmacological Mild exercise; carbohydrates Mild exercise at attack onset;
potassium supplements
Mild exercise; carbohydrates (if
attacks associated with
hypokalemia)
Potassium supplement† Not applicable Oral K1 1 mEq/kg up to 200
mEq/24h* Avoid slow release
formulations
If attacks associated with low K1,
oral K1 1 mEq/kg up to 200
mEq/12h* to normalize
Beta-2 agonist – salbutamol 2 puffs 0.1mg Not applicable Not applicable
Prevention
Non-pharmacological Frequent high carbohydrate
meals; Avoid: fasting; strenuous
exercise; cold exposure;
K1 rich foods
Low sodium and carbohydrate
diet; potassium supplements;
avoid hyperosmolar states
(dehydration, hyperglycemia)
Acetazolamide Adults: 125-1000mg daily
Children: 5-10mg/kg/d
Adults: 125-1000mg daily
Children: 5-10mg/kg/d
Adults: 125-1000mg daily
Children: 5-10mg/kg/d
Dichlorphenamide 50-200mg daily 50-200mg daily 50-200mg daily
Potassium supplement† Not applicable Oral K1 30-60 mEq/day;
sustained released formulation
may be preferred
Not applicable
K1 sparing diuretic Not applicable Triamterene 50-150mg/d
Spironolactone 25-100mg/d
Eplerenone 50-100mg/d
Not applicable‡
Hydrochlorothiazide 25-75mg daily Not applicable Not applicable
Antiarrhythmics Not applicable Not applicable Flecainide, beta-blockers or
calcium channel blockers to
prevent ventricular arrhythmias
*Monitor ECG and potassium levels.
†Total body potassium is not depleted in HypoPP, use caution with acute K1 administration to avoid overshoot.
‡Use of K-sparing diuretics should be individualized based on patient needs.
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of the attack may be of benefit. Low serum potas-
sium is not due to low total body potassium but
rather shifts of potassium from the blood compart-
ment into the intracellular muscle compartment.
Therefore, correction of serum potassium should
not be undertaken with the goal of correcting low
total body potassium. Treatment options include
oral or intravenous (IV) potassium administra-
tion.18,19 Oral potassium is recommended for outpa-
tient treatment. Slow-release formulations usually
should be avoided for acute management. The dose
of oral potassium is 0.2–0.4 mEq/kg every 30min
not to exceed 200–250 mEq/day. Administering
potassium by IV infusion usually requires hospitali-
zation for ECG monitoring but is only necessary if
the patient cannot take oral potassium. The dose of
IV potassium is 40 mEq/L in 5% mannitol solution
infused at a maximum of 20 mEq/h, not to exceed
200 mEq/day. A potassium chloride IV bolus of 5
mEq can be used as an alternative. Use of glucose-
and saline-containing IV solutions for administering
potassium should be avoided, as this may worsen
muscle weakness.55
Prevention. The patient should be advised to
avoid triggers such as high-carbohydrate and/or
high-salt meals, alcohol, and stress.2 Although no
randomized controlled studies are available to
inform dosing, a daily slow-release potassium salt
formulation may be considered the standard of
care for chronic therapy.
Dichlorphenamide is approved for HypoPP, and
has been associated with reductions in attack fre-
quency, severity, and duration during chronic treat-
ment.22,53 Based on anecdotal reports, acetazolamide
125–1000mg/day may be effective chronic treatment
of HypoPP.15,20,23,56–58 In a double-blind crossover
study, acetazolamide 125mg three times daily or pla-
cebo given for 2 weeks each was evaluated in
8 patients with HypoPP.59 Muscle strength was mea-
sured in muscle groups every week and improved
significantly in seven of eight patients. Mean
strength was significantly greater with acetazolamide
(P5 0.05), and total muscle strength increased by a
mean of 10% with treatment.
Potassium-sparing diuretics are a potential
option for chronic treatment of HypoPP.6,18 Rec-
ommended doses are triamterene 50–150mg/day,
spironolactone 25–100mg/day or eplerenone 50–
100mg daily. Spironolactone may be poorly toler-
ated because of androgenic side effects, and epler-
onone may be substituted because it causes fewer
hormonal issues. For patients with HypoPP, potas-
sium supplementation and a potassium-sparing
diuretic may be used concomitantly, but potassium
levels should be routinely monitored.
Recent studies in mouse models of HypoPP with
both SCN4A mutations and CACNA1S mutations
show that maneuvers to reduce the activity of the
Na-K-2Cl (NKCC) co-transporter can reverse an
acute attack of HypoPP and protect against an attack
triggered by low K1 exposure.60,61 The beneficial
effect is the result of biasing intracellular chloride to
be low, which promotes hyperpolarization of the
resting potential. The NKCC co-transporter is acti-
vated by hyperosmolarity (hence the importance of
avoiding high sodium diet, dehydration or hypergly-
cemia) and is inhibited by loop diuretics such as
bumetanide. Pharmacologic inhibition of NKCC as
an acute therapy for HypoPP is under study.
Management of HyperPP. Acute Management. Acute
management may include mild exercise at attack
onset and a carbohydrate snack. Beta agonists can be
an effective acute potassium-lowering therapy for
HyperPP.1 In case reports, salbutamol 1–2 puffs
(0.1mg) and other beta-agonists have shown bene-
fits.62–64 While severe hyperkalemia during attacks is
typically not seen, the treatment for acute hyperkale-
mia which is severe or life-threatening should match
institutions’ established protocols.
Prevention. In individuals with HyperPP, con-
sider recommending consumption of multiple
small carbohydrate snacks and avoid potassium-
rich foods.10
Dichlorphenamide can be effective for chronic
treatment and is approved for HyperPP.22,53 In
randomized, placebo-controlled studies, dichlor-
phenamide reduced attack frequency and severity
among patients.22,53 The initial dose is 50mg twice
daily, which may be increased or decreased at
weekly intervals based on individual response or
the occurrence of adverse events. The maximum
recommended dose is 200mg daily.22,53 Acetazol-
amide 125–1000mg/day may be effective for
chronic treatment of HyperPP.15,23
Thiazide diuretics are an option for chronic
treatment of HyperPP.1,42 The drug of choice is
hydrochlorothiazide 25mg to 75mg daily.41,54
Potassium-sparing diuretics should be avoided.
There are no rigorously controlled data on the
treatment of PMC, normokalemic PP, and other
atypical PPs, but in general, the same treatment
strategies used for HyperPP are appropriate.
Management of Andersen-Tawil Syndrome.
Management of individuals with Andersen-Tawil
syndrome requires the coordinated input of a neu-
rologist familiar with the treatment of periodic
paralysis and a cardiologist familiar with the treat-
ment of cardiac arrhythmias. Treatment for acute
attacks of weakness or for chronic suppression of
attacks of weakness in individuals with Andersen-
Tawil syndrome depends on whether the attack is
associated with high or low levels of potassium,
and treatment needs to be individualized for each
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patient (see sections above for HypoPP and
HyperPP for specific recommendations).10 Eva-
luations recommended to establish the extent of
disease and needs in a patient diagnosed with
Andersen-Tawil syndrome are summarized in Table
6.65 For asymptomatic patients with a KCNJ2 muta-
tion, annual screening should include a 12-lead
ECG and 24-h Holter monitoring.
Treatment of Manifestations. Cardiac considera-
tions. Empiric treatment with an antiarrhythmic
agent should be considered for significant, frequent
ventricular arrhythmias in the setting of reduced left
ventricular function.27,66 A prospective open label
study in 10 individuals with Andersen-Tawil syn-
drome and a confirmed KCNJ2 mutation tested the
effect of flecainide, a type 1c antiarrhythmic, for the
prevention of cardiac arrhythmias.67 Assessments
included 24-h Holter monitoring before and after
treatment, and a treadmill exercise test. Flecainide
significantly reduced the number of ventricular
arrhythmias observed on Holter monitor and sup-
pressed exercise-induced ventricular arrhythmias.
After a mean follow-up of 23 months, no syncope or
cardiac arrest was documented. Thus, flecainide
may reduce cardiac arrhythmias in Andersen-Tawil
syndrome, although further evaluation is needed.
Others have reported beneficial effects with fle-
cainide.68–70 Others report beneficial effects for
suppressing ventricular arrhythmias with the use
of beta-blockers, calcium channel blockers, or
amiodarone.27,28
Prevention of secondary complications. Some anti-
arrhythmic drugs (e.g., lidocaine, mexiletine, prop-
afenone, quinidine) may paradoxically exacerbate
neuromuscular symptoms and should be used cau-
tiously in individuals with Andersen-Tawil syn-
drome.8,24 Although malignant hyperthermia has
not been reported in Andersen-Tawil syndrome,
appropriate precautions should be undertaken
when using anesthesia for surgical procedures.
Patients should be instructed about medications
known to prolong QT intervals and avoid their
use. Inhaled salbutamol, which may be used for
the treatment of HyperPP, should be avoided
because of the potential to exacerbate cardiac
arrhythmias. Thiazide diuretics should be avoided,
because they may induce drug-induced hypokale-
mia and could aggravate the QT interval.
CONCLUSIONS AND RECOMMENDATIONS
FOR FUTURE STUDIES
Because of their low prevalence in the general
population, most experience with treatment for
these patients is obtained from anecdotal reports.
The present recommendations are based on a
review of published literature with the exception
of the Level I evidence supporting the use of
dichlorphenamide in the long-term management
of HypoPP and HyperPP.
Despite the rarity of these disorders, which cre-
ates many challenges in conducting studies in peri-
odic paralyses, more prospective studies are needed,
in particular comparing acetazolamide and dichlor-
phenamide as well as other interventions for manag-
ing patients. Studies should include long-term follow-
up, cost benefits of treatment, effects of treatment on
permanent muscle weakness, adverse events, as well
as efficacy. In the future, a better understanding of
the genetics of these disorders may lead to improved
treatment options.
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